Flame retardant ban reduces exposures in pregnant women

27-Sep-2013 - USA

Phasing out the use of potentially harmful flame retardants in furniture foam, electronics and plastics has lowered pregnant women's exposure to the substances, which are associated with health problems in both pregnant women and their newborns. The new study, which was published in the ACS journal Environmental Science & Technology, was the first to examine the phase-out's effectiveness.

Ami Zota, an assistant professor at George Washington University, and colleagues explain that furniture, electronics and plastics manufacturers commonly used flame retardants called polybrominated diphenyl ethers (PBDEs) in their products starting in the 1970s. In 2003-2004, California banned the manufacture and import of certain PBDEs, and the U.S. phased out their production. However, human exposure continues from house dust, food and use of older products containing the flame retardants. PBDEs are associated with thyroid hormone problems in pregnant women and their children. These children also are at greater risk for having poor attention spans and reduced IQs. No one knew whether the ban actually reduced human exposures, so Zota's team investigated the issue.

They found a 65 percent drop over three years (2008-2011) in the levels of PBDEs in blood samples from pregnant women who visited San Francisco General Hospital, suggesting that the ban had a positive impact. However, the authors caution that because the substances remain in the environment for a long time, exposure will likely continue. The researchers say this study shows the importance of biomonitoring (measuring the presence of substances in the human body) to track changes in levels in the human population, and the value of that information in shaping public health policy.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Peregrine Enters Contract Negotiations With U.S. DTRA for Hemorrhagic Fevers - U.S. Department of Defense Agency Has Selected Peregrine for a Multi-Year Award That Could Total $44.5 Million Pending Successful Contract Negotiations

Food safety in Europe - who is responsible for what? - BfR publishes 2. completely revised edition of the EU Food Safety Almanac

SemBioSys signs contract manufacturing agreement for plant-produced insulin with Cangene

Cellzome Achieves Clinical Candidate Milestone from Inflammation Alliance with GlaxoSmithKline

Bionomics BNC105 cancer clinical trials reach key milestones - Clinical program to be expanded

Crucell to sell Rhein Biotech GmbH to Dynavax

Active Biotech's nomination committee proposes election of an additional new board member

ITI Life Sciences licenses technology to Cognia to develop a database product to enhance drug discovery and development

Delisting of Merck Serono shares expected on July 18, 2007 - Squeeze Out Successfully Completed

Biotec Pharmacon's SBG shows promising effect in animal model for inflammatory bowel disease

MediGene Acquires Patents on Anti-Cancer Drugs Under Development - License agreements with the University of Chicago guarantee exclusive worldwide rights to the most important groups of patents in the field of oncolytic Herpes Simplex Viruses (HSV)

Novartis-Partner Antisoma stops ASA404 ovarian cancer trial